MBB Public Markets I LLC Has $18.26 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

MBB Public Markets I LLC increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,383 shares of the medical research company’s stock after purchasing an additional 7,736 shares during the period. MBB Public Markets I LLC’s holdings in Charles River Laboratories International were worth $18,258,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. APG Asset Management US Inc. bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $2,321,000. Boston Trust Walden Corp grew its holdings in Charles River Laboratories International by 2.8% in the 2nd quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock valued at $41,381,000 after buying an additional 5,375 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in shares of Charles River Laboratories International by 5.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 56,840 shares of the medical research company’s stock worth $15,401,000 after acquiring an additional 2,739 shares during the last quarter. Global Assets Advisory LLC bought a new position in Charles River Laboratories International during the first quarter worth $8,301,000. Finally, Natixis acquired a new position in Charles River Laboratories International during the 1st quarter valued at $1,058,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 2.8 %

CRL opened at $198.26 on Friday. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $10.24 billion, a PE ratio of 23.32, a PEG ratio of 4.09 and a beta of 1.36. The firm has a 50-day moving average price of $207.54 and a two-hundred day moving average price of $222.21. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.41. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has approved a stock repurchase program on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to buy up to 9.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. TD Cowen reduced their target price on shares of Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research note on Monday, August 12th. Mizuho started coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They set a “neutral” rating and a $235.00 price objective for the company. The Goldman Sachs Group decreased their price objective on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Finally, Evercore ISI cut their price objective on Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Ten investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $227.55.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).